Submit a Release
Home
All
ESG
Health
Technology
Finance
Contributors
Sub Menu
Submit a Release
main-search-pop
Main menu
/C O R R E C T I O N -- Gesynta Pharma/
Contributed by:
PR Newswire
Tags
Gesynta-Pharma
More Like This
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat
Gynica announces First-in-Human Clinical Trial of Novel IntraVag© Treatment for Endometriosis
Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation
Gedeon Richter: Medical Treatment of Endometriosis with a progressive approach
Organon to Present New Research on Access and Value at ISPOR 2026
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures
Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference
Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
